J 2021

Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial

ADER, Florence, Nathan PEIFFER-SMADJA, Julien POISSY, Maude BOUSCAMBERT-DUCHAMP, Drifa BELHADI et. al.

Basic information

Original name

Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial

Authors

ADER, Florence, Nathan PEIFFER-SMADJA, Julien POISSY, Maude BOUSCAMBERT-DUCHAMP, Drifa BELHADI, Alpha DIALLO, Christelle DELMAS, Juliette SAILLARD, Aline DECHANET, Noémie MERCIER, Axelle DUPONT, Toni ALFAIATE, François-Xavier LESCURE, François RAFFI, François GOEHRINGER, Antoine KIMMOUN, Stéphane JAUREGUIBERRY, Jean REIGNIER, Saad NSEIR, François DANION, Raphael CLERE-JEHL, Kévin BOUILLER, Jean-Christophe NAVELLOU, Violaine TOLSMA, André CABIE, Clément DUBOST, Johan COURJON, Sylvie LEROY, Joy MOOTIEN, Rostane GACI, Bruno MOURVILLIER, Emmanuel FAURE, Valérie POURCHER, Sébastien GALLIEN, Odile LAUNAY, Karine LACOMBE, Jean-Philippe LANOIX, Alain MAKINSON, Guillaume MARTIN-BLONDEL, Lila BOUADMA, Elisabeth BOTELHO-NEVERS, Amandine GAGNEUX-BRUNON, Olivier EPAULARD, Lionel PIROTH, Florent WALLET, Jean-Christophe RICHARD, Jean REUTER, Thérèse STAUB, Maya HITES, Marion NORET, Claire ANDREJAK, Gilles PEYTAVIN, Bruno LINA, Dominique COSTAGLIOLA, Yazdan YAZDANPANAH, Charles BURDET and France MENTRE

Edition

medRxiv 20218149 [Preprint], London, Cold Spring Harbor Laboratory Press, 2021, 1756-1833

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30230 Other clinical medicine subjects

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 93.333

RIV identification code

RIV/00216224:14110/21:00124332

Organization unit

Faculty of Medicine

Keywords (in Czech)

COVID-19; SARS-CoV-2; hydroxychloroquine; interferon beta-1a; lopinavir/ritonavir; randomized controlled trial

Keywords in English

COVID-19; SARS-CoV-2; hydroxychloroquine; interferon beta-1a; lopinavir/ritonavir; randomized controlled trial

Tags

International impact
Změněno: 1/3/2022 12:35, Bc. Hana Vladíková, BBA

Abstract

V originále

Background Lopinavir/ritonavir, lopinavir/ritonavir-interferon (IFN)-β-1a and hydroxychloroquine efficacy for COVID-19 have been evaluated, but detailed evaluation is lacking. Objective To determine the efficacy of lopinavir/ritonavir, lopinavir/ritonavir-IFN-β-1a, hydroxychloroquine or remdesivir for improving the clinical, virological outcomes in COVID-19 inpatients. Design Open-label, randomized, adaptive, controlled trial.

Links

90128, large research infrastructures
Name: CZECRIN III